NCT05465343 2025-12-19Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)Peking Union Medical CollegePhase 2 Completed24 enrolled
NCT04671303 2025-05-11To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Completed36 enrolled